VANCOUVER, BC / ACCESSWIRE / May 5, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the successful completion of its human performance study for the Gemina Legio XTM COVID-19 Rapid Antigen test, a significant development milestone demonstrating the power of Gemina's novel patented chemistry.
Gemina Labs initiated human clinical performance studies which began in early April 2022 at the Centro Diagnostico Buonarroti (Buonarroti Diagnostic Center - "CDB") in Civitavecchia, Italy. CDB is a leading health facility with expertise in the provision of diagnostic testing and clinical analysis for Italy's general population, with a specific expertise in COVID-19 testing. After four weeks of patient testing and the administration of more than 500 Gemina Legio XTM COVID-19 Rapid Antigen Tests, the real-world data has revealed exceptionally strong performance results. The performance data benchmarked against the gold standard of PCR test results continues to exceed expectations and further supports upcoming regulatory submissions.
Importantly, the Gemina Legio XTM COVID-19 test was administered with a shallow (anterior) nasal swab, which showed comparable sensitivity and specificity to one of the most widely distributed and best performing rapid COVID tests in Europe and the United Kingdom. To achieve the performance demonstrated by Gemina's Legio XTM test, the comparator test was required to be administered using the much more invasive nasopharyngeal (deep nasal) swab, which can only safely be administered by a healthcare professional. This important ‘form of administration' advantage suggests that the Gemina Legio XTM test has the potential to deliver clinical performance results using a much less invasive sampling method that can be performed without the assistance of a healthcare professional.
"During the first waves of the COVID pandemic, when the wild-type and Alpha variants were circulating, our preferred CE-marked rapid test performed sufficiently well with shallow nasal swabs to show correlation with PCR in the high 90th percentile," commented Dr. Carlo Tarantino, the lead clinician at Centro Diagnostico Buonarroti. "However, because of the way the Delta and Omicron variants have evolved, we were compelled to switch to nasopharyngeal swabs to provide sufficient sensitivity. When the Gemina team proposed to evaluate the performance of the Legio XTM test using shallow nasal swabs, I cautioned them not to be disappointed if their test did not perform well in comparison. However, after the first week of testing, I was very impressed to see the Gemina test providing equivalent sensitivity with a shallow swab as the comparator test was generating with a deep nasopharyngeal swab. This high performance of the Gemina Legio XTM test persisted throughout the study and as soon as it becomes commercially available, I would add the Gemina Legio XTM test to our inventory. Patients, especially children, much prefer the less invasive sample method."
The successful completion of the clinical performance study provides Gemina with the sensitivity and specificity data required to support its regulatory submissions in advance of the commercial rollout of the Gemina Legio XTM COVID-19 Rapid Antigen Test. In addition to moving the COVID test one step closer to commercialization, the superb performance of the test in such a clinical setting validates the Gemina chemistry platform that lies at the heart of the diagnostic device. The Company has proven that its novel chemistry can be used to design and build a very high-quality point-of-care assay that can be manufactured at scale and reliably used for patient diagnosis. This gives Gemina the confidence to expand its development program beyond COVID to new respiratory infection targets and beyond, which will further demonstrate the universal applicability of the Gemina chemistry platform.
Robert Greene, CTO of Gemina Labs stated, "We are extremely pleased by the consistently strong performance of our Legio-XTM COVID test. The independent data collected to date shows that we not only can exceed the performance of leading shallow nasal swab rapid antigen tests currently on the market, but also meet or exceed leading deep nasal swabs as administered by healthcare professionals. This provides us with great confidence that out chemistry platform is very robust, and has the ability to power the next generation of point of care testing, whether in the clinic or at home."
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 virus. The Company will be seeking regulatory approval for our product(s) before sales and clinical use are permitted.
On Behalf of the Board of Directors
John Davies CEO Gemina Laboratories Ltd.
Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at www.geminalabs.com.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.
For more information regrading the Company, please contact:
James Tansey Telephone: 604-562-4546 Email: investor@geminalabs.com
View source version on accesswire.com: https://www.accesswire.com/700276/Gemina-Labs-Completes-Successful-Human-Clinical-Performance-Evaluation-on-its-Legio-X-COVID-19-Rapid-Antigen-Test
Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time. More quarantine time "is not a crowd-pleaser," Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. Use of Pfizer's Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen.
While many of us optimistically hoped that the coronavirus would be a distant memory at this point, that is hardly the reality. We entered 2022 in one of the worst surges throughout the entire pandemic, with the Omicron variant creating record high infection numbers across the U.S. And despite COVID numbers falling substantially throughout February and March, they are back on the rise again. In the last week, the U.S. has reported an average of almost 110,000 new infections every day, according
CDC identifies 9 monkeypox cases across 7 states
Although the two diseases share many symptoms, there are several key differences
The cases, which have so far puzzled health officials, have been reported in 33 different countries since early April.
Some prominent infectious disease experts are pushing for faster action from global health authorities to contain a growing monkeypox outbreak that has spread to at least 20 countries. They are arguing that governments and the World Health Organization should not repeat the early missteps of the COVID-19 pandemic that delayed the detection of cases, helping the virus spread. While monkeypox is not as transmissible or dangerous as COVID, these scientists say, there needs to be clearer guidance on how a person infected with monkeypox should isolate, more explicit advice on how to protect people who are at risk, and improved testing and contact tracing.
None of these are legit, even though they were shared widely on social media. CLAIM: Photos shared on Reddit of a woman — wearing a Coca-Cola sweatshirt and black skirt in one picture and a NASA shirt in another — show Salvador Ramos, who officials say fatally shot 19 children and two teachers in Uvalde, Texas. Another photo of a woman holding a green bottle to her mouth also shows Ramos.
Each week, we offer you a roundup of noteworthy coronavirus coverage.
With one of Europe's largest gay pride celebrations right around the corner, Spain's LGBTQ community is worried that the outbreaks of monkeypox on the continent could lead to an increase in homophobic sentiment based on misunderstandings of the disease. Spanish health authorities said Friday there were now 98 confirmed cases in the country, the highest number in Europe.
Seven nasal vaccines for COVID-19 are currently in clinical trials around the world. VSargues/iStock via Getty ImagesImagine inhaling just a few drops of liquid or mist to get protected from COVID-19. That is the idea behind nasal COVID-19 vaccines, and they have been getting a lot of attention recently as a spray or liquid. These nasal vaccines would be based on the same technology as normal vaccines given by injection. But as Mayuresh Abhyankar, a University of Virginia researcher who studies
The U.S. Centers for Disease Control and Prevention has identified cases of monkeypox in California, Colorado, Florida, Massachusetts, New York, Utah, Virginia and Washington
Tick season is here and a little caution and common sense can help you avoid serious diseases like Lyme, anaplasmosis and babesiosis.
After a long, dreary period of lingering close to zero, short-term yields are on the rise, so we asked advisors for their thoughts on the best places for clients to stash the cash portion of their portfolios. Richard Skae, vice chairman of Morgan Stanley Wealth Management Group, has died at age 65. Skae served as vice chair since 2017, and was credited as “absolutely instrumental to the success of our firm” by Andy Saperstein, co-president of Morgan Stanley and head of the wealth management division.
Asian shares gained Friday as investors cheered a strong set of earnings from retailers that has sent U.S. shares higher.
(Bloomberg) -- Baidu Inc. shares jumped more than 12% on Friday after the Chinese internet search leader posted a surprise quarterly revenue gain, reassuring investors spooked by the impact of Covid lockdowns.Most Read from BloombergFord Beats Tesla to the Punch With First Electric F-150 DeliveryUkraine Latest: US Slams Putin’s Food-for-Sanctions Relief PlanTop Gun: Maverick's F-18 Flights Cost New Tom Cruise Film $11,374 an HourRare Ship-to-Ship Transfers Keep Oil Moving From Russia to ChinaSal
Leesburg quantum computing software company Quantum Computing Inc. (NASDAQ: QUBT) is purchasing fellow quantum firm QPhoton Inc. in its first M&A deal. The acquisition will be paid for by a mixture of common stock, preferred stock and warrants and will represent in total approximately 49% of the total outstanding capital stock of QCI. Quantum Computing Inc., or QCI, began trading on the Nasdaq in July after three years on the over-the-counter market.
Solid first-quarter results are sending shares of the beauty products retailer higher, but the question is whether that strong move will hold.
Aurora Cannabis Inc. shares dropped 28% Friday after the cannabis company said it would increase the size of its bought deal financing to $150 million from $125 million. A syndicate of underwriters led by Canaccord Genuity and BMO Capital Markets will buy on a bought deal basis 61.2 million units of the company at a price of $2.45 per unit for gross proceeds of approximately $150 million. Each Unit will be comprised of one common share and one common share purchase warrant exercisable for 36 mon
(Bloomberg) -- State-owned automaker China FAW Group Co. is considering acquiring a significant stake in the troubled ride-hailing giant Didi Global Inc., according to people familiar with the matter.Most Read from BloombergElon Musk Says Bill Gates Has ‘Multi-Billion Dollar’ Tesla Short PositionRussian Wins in Eastern Ukraine Spark Debate Over Course of WarFord Beats Tesla to the Punch With First Electric F-150 DeliveryBitcoin Breaks From Stocks and Keeps On Falling as Crypto SlidesUkraine Late
Gold is 0.4% higher this morning, as it is trading above the $1,850 price level. What about the other precious metals?